高尔基体糖蛋白73及过氧化物酶3与慢性乙肝相关性肝癌患者预后的关系

doi:10.3969/j.issn.1671-7171.2024.10.027

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1214 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨高尔基体糖蛋白73(GP73)及过氧化物酶3(MPO3)与慢性乙肝(CHB)相关性肝癌预后的关系。【方法】以101例CHB相关性肝癌患者为观察组,90例健康志愿者为对照组。比较两组血清GP73、MPO3水平。随访2年,统计观察组患者生存情况,并据此分为死亡组(21例)和存活组(80例),比较死亡组和存活组患者的临床资料,分析影响患者预后的危险因素GP73、MPO3及两者联合检测对患者预后的预测效能。【结果】观察组GP73水平高于对照组,MPO3水平低于对照组(P<0.05)。CHB相关性肝癌患者病死率为20.79%(21/101)。死亡组患者Ⅲ~Ⅳ期占比、低分化占比、肿瘤最大直径＞5 cm占比、肿瘤数目＞2个占比、淋巴结转移占比、GP73均高于存活组,MPO3低于存活组(P<0.05)。Logistic回归分析显示,临床分期、GP73及MPO3均为患者预后的影响因素(P<0.05)。受试者工作特征(ROC)曲线分析显示,GP73、MPO3及两者联合检测预测患者预后的曲线下面积(AUC)分别为0.803、0.717和0.913。【结论】血清GP73、MPO3与CHB相关性肝癌患者的预后存在一定的相关性,且两者联合对患者预后的预测效能较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	宋芝峰

关键词 ：肝肿瘤/外科学, 乙型肝炎病毒, 慢性病, 高尔基体基质蛋白质类, 过氧化物酶

Abstract：【Objective】 To explore the relationship between of Golgi protein 73 (GP73) and myeloperoxidase 3 (MPO3) with the prognosis of hepatocellular carcinoma (HCC) related to chronic hepatitis B (CHB).【Methods】 The study involved included 104 patients with CHB-related HCC as the observation group and 90 healthy volunteers as the control group. Serum levels of GP73 and MPO3 were compared between the two groups. A two-year follow-up was conducted to track the survival of the observation group. Based on survival outcomes, patients of the observation group were divided into the death group (21 cases) and the survival group (80 cases). Clinical data between the death and survival groups were compared, and risk factors affecting patient prognosis were analyzed. The predictive efficiency of GP73, MPO3, and their combined detection for patient prognosis was evaluated.【Results】 The GP73 level in the observation group was higher than that in the control group, while the MPO3 level was lower (P<0.05). The mortality rate of CHB-related HCC patients was 20.79% (21/101). The death group had higher proportions of patients in stage Ⅲ~Ⅳ, poorly differentiated tumors, maximum tumor diameter >5 cm, multiple tumors (>2), lymph node metastasis compared to the survival group, and elevated the level of GP73 was higher levels, with and lower MPO3 levels was lower in the death group than those in the survival group (P<0.05). Logistic regression analysis showed that clinical stage, GP73, and MPO3 were factors influencing patient prognosis (P<0.05). Receiver operating characteristic (ROC) curve analysis revealed that the area under the curve (AUC) for predicting patient prognosis using GP73, MPO3 alone, and their combined detection was 0.803, 0.717, and 0.913, respectively.【Conclusion】 Serum GP73 and MPO3 levels are correlated with the prognosis of CHB-related HCC patients. The combined detection of these two markers shows a higher predictive efficiency for patient prognosis.

Key words： Liver Neoplasms/SU Hepatitis B Virus Chronic Disease Golgi Matrix Proteins Peroxidase

收稿日期: 2023-10-20

中图分类号:

R735.7

引用本文:

宋芝峰. 高尔基体糖蛋白73及过氧化物酶3与慢性乙肝相关性肝癌患者预后的关系[J]. 医学临床研究, 2024, 41(10): 1550-1553.
SONG Zhifeng. Relationship between of Golgi Protein 73 and Myeloperoxidase 3 with the Prognosis of Chronic Hepatitis B-related Hepatocellular Carcinoma Related to Chronic Hepatitis B. JOURNAL OF CLINICAL RESEARCH, 2024, 41(10): 1550-1553.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.10.027 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I10/1550

[1] 焦月琴, 赵云峰, 刘小壮, 等. 肝癌患者外周血γδ T细胞比例及功能变化研究[J].实用预防医学, 2020, 27(7):884-888.
[2] LIANG Y J, TENG W, CHEN C L, et al. Clinical implications of HBV PreS/S mutations and the effects of PreS2 deletion on mitochondria, liver fibrosis, and cancer development[J].Hepatology,2021,74(2):641-655.
[3] 童正喜, 张克昌, 郑奇. 血清高尔基体糖蛋白73、甲胎蛋白、CHI3L1在肝癌中的诊断价值及与患者预后的关系[J].热带医学杂志, 2020, 20(6):779-782.
[4] 李洪利,俞魏,陈彤岩,等. 甲状腺癌患者血清半乳糖凝集素-1、谷胱甘肽过氧化物酶3表达变化及其与疾病严重程度相关性研究[J].中华保健医学杂志,2020,22(2):191-193.
[5] 梁栋,李娜,杨秦蘅,等. LINC01133/微小RNA-205/谷胱甘肽过氧化物酶3轴对乳腺癌细胞增殖和迁移的影响[J].中华实验外科杂志,2020,37(12):2306-2309.
[6] LEOMO S, PISCAGLLIA F, SERIO I, et al. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group[J].Dig Liver Dis,2014,46(6):549-555.
[7] ROBOTIN M C, WALLACE J, GALLEGO G, et al. Hepatitis B and liver cancer: community awareness, knowledge and beliefs of middle eastern migrants in Sydney, Australia[J].Int J Environ Res Public Health,2021,18(16): 28-31.
[8] 王晨宇, 华龙, 李兴旺, 等. 长链非编码RNA核富集转录体1在HBV感染相关性肝癌中的表达及意义[J].中华医院感染学杂志, 2021, 31(21):3235-3239.
[9] 陈超, 姚玲, 邱邦东, 等. GP73与铁调素在HBV相关性肝癌患者血清中表达变化及与预后的相关性[J].肝脏, 2021, 26(9):1007-1010.
[10] AKPINAR M Y, SIMSEK G G, AKSOY E K, et al. Survivin expression starts before hepatocellular cancer development in the liver of chronic hepatitis B patients: a pilot, cross-sectional study[J].Prz Gastroenterol,2020,15(2):138-143.
[11] SU F, WEISS N S, BESTE L A, et al. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B[J].J Hepatol,2021,74(4):850-859.
[12] 李欢, 韩素桂, 董宇曦. HBV相关原发性肝癌患者外周血MIF、GP73、VPIKA-Ⅱ的表达及意义[J].国际检验医学杂志, 2021, 42(10):1171-1175.
[13] 仝麟龙,张俊杰. 血清过氧化物酶3在原发性肝癌中的诊断价值及其对预后的影响研究[J].中国全科医学,2020,23(32):4096-4103.
[14] 张珂,单艳华. 人软骨糖蛋白、过氧化物酶3预测ICU大范围肝切除肝癌患者预后的临床价值[J].实用癌症杂志,2023,38(3):407-410.